305 related articles for article (PubMed ID: 18976644)
1. Arylesterase and paraoxonase activity of paraoxonase (PON1) affected by ischemia in the plasma of patients with arterial occlusion of the lower limbs.
Kasprzak M; Iskra M; Majewski W; Wielkoszyński T
Clin Biochem; 2009 Jan; 42(1-2):50-6. PubMed ID: 18976644
[TBL] [Abstract][Full Text] [Related]
2. Paraoxonase/arylesterase ratio, PON1 192Q/R polymorphism and PON1 status are associated with increased risk of ischemic stroke.
Can Demirdöğen B; Türkanoğlu A; Bek S; Sanisoğlu Y; Demirkaya S; Vural O; Arinç E; Adali O
Clin Biochem; 2008 Jan; 41(1-2):1-9. PubMed ID: 17920578
[TBL] [Abstract][Full Text] [Related]
3. Oxidative status and serum PON1 activity in beta-thalassemia minor.
Selek S; Aslan M; Horoz M; Gur M; Erel O
Clin Biochem; 2007 Mar; 40(5-6):287-91. PubMed ID: 17296173
[TBL] [Abstract][Full Text] [Related]
4. Paraoxonase (PON1) polymorphism and activity as the determinants of sensitivity to organophosphates in human subjects.
Sirivarasai J; Kaojarern S; Yoovathaworn K; Sura T
Chem Biol Interact; 2007 Jul; 168(3):184-92. PubMed ID: 17532308
[TBL] [Abstract][Full Text] [Related]
5. PON1 status in haemodialysis patients and the impact of hepatitis C infection.
Horoz M; Aslan M; Selek S; Koylu AO; Bolukbas C; Bolukbas FF; Celik H; Erel O
Clin Biochem; 2007 Jun; 40(9-10):609-14. PubMed ID: 17335792
[TBL] [Abstract][Full Text] [Related]
6. Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus.
Ali EM; Shehata HH; Ali-Labib R; Esmail Zahra LM
Clin Biochem; 2009 Sep; 42(13-14):1394-400. PubMed ID: 19538950
[TBL] [Abstract][Full Text] [Related]
7. Inherited and acquired interactions between ACHE and PON1 polymorphisms modulate plasma acetylcholinesterase and paraoxonase activities.
Bryk B; BenMoyal-Segal L; Podoly E; Livnah O; Eisenkraft A; Luria S; Cohen A; Yehezkelli Y; Hourvitz A; Soreq H
J Neurochem; 2005 Mar; 92(5):1216-27. PubMed ID: 15715671
[TBL] [Abstract][Full Text] [Related]
8. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population.
Elkiran ET; Mar N; Aygen B; Gursu F; Karaoglu A; Koca S
BMC Cancer; 2007 Mar; 7():48. PubMed ID: 17362500
[TBL] [Abstract][Full Text] [Related]
9. Baseline and salt-stimulated paraoxonase and arylesterase activities in patients with chronic liver disease: relation to disease severity.
Keskin M; Dolar E; Dirican M; Kiyici M; Yilmaz Y; Gurel S; Nak SG; Erdinc S; Gulten M
Intern Med J; 2009 Apr; 39(4):243-8. PubMed ID: 19402863
[TBL] [Abstract][Full Text] [Related]
10. Levels of paraoxonase and arylesterase activities and malondialdehyde in workers exposed to ionizing radiation.
Serhatlioglu S; Gursu MF; Gulcu F; Canatan H; Godekmerdan A
Cell Biochem Funct; 2003 Dec; 21(4):371-5. PubMed ID: 14624476
[TBL] [Abstract][Full Text] [Related]
11. Paraoxonase and arylesterase activity and total oxidative/anti-oxidative status in patients with chronic adenotonsillitis.
Koc S; Aksoy N; Bilinc H; Duygu F; Uysal IÖ; Ekinci A
Int J Pediatr Otorhinolaryngol; 2011 Nov; 75(11):1364-7. PubMed ID: 21893350
[TBL] [Abstract][Full Text] [Related]
12. Paraoxonase/arylesterase in serum of patients with type II diabetes mellitus.
Juretić D; Motejlkova A; Kunović B; Rekić B; Flegar-Mestrić Z; Vujić L; Mesić R; Lukac-Bajalo J; Simeon-Rudolf V
Acta Pharm; 2006 Mar; 56(1):59-68. PubMed ID: 16613735
[TBL] [Abstract][Full Text] [Related]
13. Paraoxonase phenotype distribution in a healthy Iranian population.
Sepahvand F; Shafiei M; Ghaffari SM; Rahimi-Moghaddam P; Mahmoudian M
Basic Clin Pharmacol Toxicol; 2007 Aug; 101(2):104-7. PubMed ID: 17651311
[TBL] [Abstract][Full Text] [Related]
14. Paraoxonase and arylesterase activities in coronary artery disease.
Gur M; Aslan M; Yildiz A; Demirbag R; Yilmaz R; Selek S; Erel O; Ozdogru I
Eur J Clin Invest; 2006 Nov; 36(11):779-87. PubMed ID: 17032345
[TBL] [Abstract][Full Text] [Related]
15. Discordance in human paraoxonase-1 gene between phenotypes and genotypes in chronic kidney disease.
Paragh G; Seres I; Harangi M; Pocsai Z; Asztalos L; Locsey L; Szeles G; Kardos L; Varga E; Karpati I; Adany R
Nephron Clin Pract; 2009; 113(1):c46-53. PubMed ID: 19602899
[TBL] [Abstract][Full Text] [Related]
16. Serum PON1 arylesterase activity in relation to hyperhomocysteinaemia and oxidative stress in young adult central retinal venous occlusion patients.
Angayarkanni N; Barathi S; Seethalakshmi T; Punitham R; Sivaramakrishna R; Suganeswari G; Tarun S
Eye (Lond); 2008 Jul; 22(7):969-74. PubMed ID: 18084236
[TBL] [Abstract][Full Text] [Related]
17. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
Dirican M; Akca R; Sarandol E; Dilek K
J Nephrol; 2004; 17(6):813-8. PubMed ID: 15593056
[TBL] [Abstract][Full Text] [Related]
18. Paraoxonase and arylesterase activities in untreated dipper and non-dipper hypertensive patients.
Yildiz A; Gur M; Demirbag R; Yilmaz R; Akyol S; Aslan M; Erel O
Clin Biochem; 2008 Jul; 41(10-11):779-84. PubMed ID: 18355454
[TBL] [Abstract][Full Text] [Related]
19. [Low paraoxonase and arylesterase plasma activities in Mexican patients with coronary artery disease].
Gamboa R; Regalado JC; Huesca-Gómez C; Posadas-Romero C; Verdejo Paris J; Vargas-Alarcón G; Pérez-Méndez O
Arch Cardiol Mex; 2008; 78(4):360-8. PubMed ID: 19205543
[TBL] [Abstract][Full Text] [Related]
20. Genetic polymorphisms and activity of PON1 in a Mexican population.
Rojas-García AE; Solís-Heredia MJ; Piña-Guzmán B; Vega L; López-Carrillo L; Quintanilla-Vega B
Toxicol Appl Pharmacol; 2005 Jun; 205(3):282-9. PubMed ID: 15922013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
